Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Aidence B.V.. (2/20/19). "Press Release: Aidence Raises €10 Million Series A to Revolutionise the Medical Imaging Industry".

Organisations Organisation Aidence B.V.
  Organisation 2 Inkef Capital B.V.
  Group ABP (Stichting Pensioenfonds) (Group)
Products Product Veye Chest AI-enabled pulmonary nodule management assistant
  Product 2 venture capital
Index term Index term Aidence–SEVERAL: investment, 201902 financing round Series A €10m led by Inkef Capital + co-investor Rabo Ventures et al
Persons Person Harte, Mark-Jan (Aidence 201902 CEO + Co-Founder)
  Person 2 van Duffelen, Jeroen (Aidence 201902 COO + Co-Founder)

As Aidence we are proud to announce we have completed a €10 million Series A funding round. The round was led by INKEF Capital and co-investor Rabo Ventures, alongside our existing investors Northzone, HenQ and Health Innovations. This investment brings Aidence’s total funding to €12.5 million.

Aidence was founded in Amsterdam in 2015 by Mark-Jan Harte (CEO) and Jeroen van Duffelen (COO). Since then, the company has made waves in the medical imaging industry with its AI solution, Veye Chest. Lung cancer is one of the most common cancers worldwide and early detection is of great importance for survival. Aidence's AI-enabled pulmonary nodule management assistant, Veye Chest, connects with existing imaging infrastructure and enables radiologists to better spot and track changes in pulmonary nodules. Veye Chest is already installed in more than 10 hospitals in the Netherlands, United Kingdom and Scandinavia and processes hundreds of studies per week.

Aidence was selected for SBRI Healthcare last year, an NHS innovation initiative. Its health economics team recognised Veye Chest has potential to provide relief to the pressures in the radiologist workforce and reduce the number of missed lung cancers. At the European Congress of Radiology, Europe’s largest radiology show in Vienna later this month, the world-renowned Royal Infirmary of Edinburgh hospital and the Edinburgh imaging facility QMRI will also present four abstracts as result of the collaboration on clinical validation for Veye Chest. (Booth AI-18 - AIX theatre - book your spot)

Since day one, we have been determined to deliver a tangible clinical AI solution that can be used by healthcare professionals to help their patients. We welcome INKEF and Rabo Ventures on our journey as we strive to shape the future of the medical imaging industry. With this funding we will continue building our European market expansion while also building towards FDA clearance giving us access to the US healthcare market. This investment will allow our research and development team to expand and explore new avenues for the Veye platform to support our radiologist AI pioneers and the patients they care for.

Our stellar team is a mix of data scientists, software engineers and medical industry professionals. In the coming months we look forward to expanding our technical and commercial teams to achieve growth and make an impact for medical professionals and patients. Interested to join our team? Learn more about our open positions here.

For more information contact Jeroen van Duffelen at or +31 (0) 6 2854 1275.

Record changed: 2019-03-06


Picture EBD Group Global Partnering Four Events One Price 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top